

Supplemental Table I. Full cohort Lp(a) levels and isoform size (N=39)**Plasma Lp(a) levels (nmol/L)**

Study Arm	Subject Number	Period 1	Period 2	apo(a) isoforms (number of Kringle 4 domains)		
S-ANA	1	134.4	96.7	19	/	20
S-ANA	2	199.7	123.4	18	/	25
S-ANA	3	42.0	13.2	28	/	31
S-ANA	4	211.5	205.9	17	/	31
S-ANA	5	164.4	83.4	24	/	27
S-ANA	6	34.8	15.8	26	/	30
S-ANA	7	0.2	0.2	28	/	-
S-ANA	8	236.3	223.8	17	/	23
S-ANA	9**	20.6	6.7	23	/	25
S-ANA	10	20.4	14.0	30	/	35
S-ANA	11	277.0	265.0	14	/	19
S-ANA	12	29.7	16.4	21	/	32
S-ANA	13	59.6	31.3	20	/	22
S-ANA	14*	21.5	16.7	28	/	-
S-ANA	15	133.0	128.0	22	/	19
S-ANA	16	1.4	0.2	32	/	28
S-ANA	17	5.3	2.7	32	/	34
S-ANA	18	17.9	13.3	25	/	36
S-ANA	19	30.4	28.9	28	/	19
S-ANA	20	7.0	5.2	20	/	23
S-ANA	21	1.3	0.7	31	/	33
S-ANA	22	15.2	3.7	23	/	27
S-ANA	23	43.7	37.3	25	/	29
S-ANA	24	5.2	4.3	28	/	30
S-ANA	25	108.1	87.0	18	/	28
S-ANA	26	209.3	180.6	16	/	25
S-ANA	27	1.0	0.3	26	/	31
S-ANA	28	9.9	9.1	18	/	23
S-ANA	29	17.2	9.0	19	/	26
P-ANA	30	13.6	8.8	28	/	34
P-ANA	31*	22.2	16.1	13	/	28
P-ANA	32	1.2	0.7	32	/	34
P-ANA	33	68.8	47.8	23	/	28
P-ANA	34	46.2	26.2	29	/	26
P-ANA	35	0.9	0.1	28	/	30
P-ANA	36	20.1	24.8	27	/	29
P-ANA	37	10.5	8.4	19	/	28
P-ANA	38	11.9	6.8	18	/	31
P-ANA	39	123.4	106.9	-	/	-

S-ANA: Atorvastatin-Anacetrapib Arm, P-ANA: Placebo-Anacetrapib Arm

*Met inclusion criteria but did not have adequate sample volumes remaining after completion of prior (main) studies.

**Met baseline inclusion criteria but post treatment Lp(a) levels were below the sensitivity of the LC/MS method.

Supplemental Table II. Individual Subject apo(a) concentrations, fractional clearance rates and production rates.

	Subject Number	Pool Size	Pool Size	FCR	FCR	PR	PR	% Δ	% Δ	% Δ
		apo(a)	apo(a)					apo(a)	FCR	PR
		nM	nM	pools/d	pools/d	nmol/kg/d	nmol/kg/d			
	Period 1	Period 2	Period 1	Period 2	Period 1	Period 2				
S-ANA	1	134.40	96.70	0.179	0.159	1.084	0.691	-28%	-11%	-36%
S-ANA	2*	199.70	123.40	0.155	0.253	1.397	1.403	-38%	63%	0%
S-ANA	3	42.00	13.20	0.344	0.386	0.650	0.229	-69%	12%	-65%
S-ANA	5*	164.40	83.40	0.143	0.372	1.054	1.398	-49%	161%	33%
S-ANA	6	34.80	15.80	0.316	0.475	0.495	0.338	-55%	50%	-32%
S-ANA	10	20.40	14.00	0.413	0.459	0.380	0.289	-31%	11%	-24%
S-ANA	12	29.70	16.40	0.385	0.378	0.514	0.279	-45%	-2%	-46%
S-ANA	13	59.60	31.30	0.389	0.417	1.042	0.588	-47%	7%	-44%
S-ANA	23	43.70	37.30	0.299	0.159	0.588	0.267	-15%	-47%	-55%
S-ANA	25	108.10	87.00	0.086	0.075	0.420	0.293	-20%	-13%	-30%
P-ANA	33	68.80	47.80	0.346	0.259	1.072	0.557	-31%	-25%	-48%
P-ANA	34	46.20	26.20	0.305	0.294	0.634	0.346	-43%	-4%	-45%

*Data from the two subjects who had no change or increase in PR.